Ochsner Brings Clinical Cancer Trials to More Patients
A new program offers access to innovative therapies and care team support
The Ochsner Cancer Institute has announced its new Precision Cancer Therapies program, which expands patient access to new cancer treatment techniques. This program gives cancer patients across the Gulf Coast region access to early-phase clinical cancer trials that were previously unavailable in the area, allowing these patients to receive innovative cancer therapies before they become widely available.
Ochsner cited Epic’s software as an important benefit to patients, as patients can choose to visit any Ochsner facility for treatment and know that their records are accessible. The amount of patient data already available in Epic will help research nurses to determine which patients are eligible for these trials, without requiring the patients to travel.
“We are providing access to cutting-edge therapies close to home, allowing patients to stay near their family during treatment and follow-up,” said Dr. Marc Matrana, medical director for Ochsner’s Precision Cancer Therapies Program.
Patients who participate in these trials also have access to a full care team dedicated to early phase cancer trial patients, from nurses and doctors to infusion staff and schedulers.
Read more here.